Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14420588 | 1.00 | KDM4E (0.44) | KDM4EKMT2ACYP19A1CYP17A1CYP26A1 | |
| SCHEMBL28434333 | 0.93 | KDM4E (0.40) | KDM4EKMT2ACYP19A1CYP17A1 | |
| SCHEMBL7283189 | 0.89 | KDM4E (0.42) | KDM4EKMT2ACYP19A1CYP17A1 | |
| SCHEMBL18546634 | 0.83 | — | — | |
| SCHEMBL25067255 | 0.82 | KDM4E (0.45) | KDM4EKMT2ACYP19A1CYP17A1CYP26A1 | |
| SCHEMBL571582 | 0.82 | CYP17A1 (0.47) | KDM4EKMT2ACYP19A1CYP17A1 | |
| SCHEMBL17598731 | 0.82 | CYP17A1 (0.47) | KDM4EKMT2ACYP19A1CYP17A1 | |
| SCHEMBL27742029 | 0.82 | CYP17A1 (0.47) | KDM4EKMT2ACYP19A1CYP17A1 | |
| SCHEMBL14415951 | 0.81 | CYP17A1 (0.37) | KDM4ECYP19A1CYP17A1CYP26A1 | |
| Iodide SCHEMBL13518969 | 0.80 | CYP17A1 (0.46) | KDM4EKMT2ACYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106018519-A | Ionic liquid functional composite membrane modified electrode and preparation method and application thereof to detection of chlorophenol | 青岛科技大学 | 2016-10-12 | — | — | CN | claimed |
| US-20250283073-A1 | Circular RNA Compositions and Methods | ORNA THERAPEUTICS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250268828-A1 | Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides | ORNA THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| US-12297285-B2 | Circular RNA encoding chimeric antigen receptors targeting BCMA | ORNA THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4543912-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | Orna Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119816517-A | Cyclic RNA encoding chimeric antigen receptor targeting BCMA | 奥纳治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-118103514-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4352234-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240052049-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240042015-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-4753944-A | INHIBITING THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1988-06-28 | — | — | US | disclosed |
| US-4728663-A | HYPOTENSIVE, ANTIARRHYTHMIA | AMERICAN CYANAMID COMPANY (US) | 1988-03-01 | — | — | US | disclosed |
| US-4710502-A | THROMBOXANE SYNTHETASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0230035-A2 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4568687-A | THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4555519-A | Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]pyridinecarboxamides | AMERICAN CYANAMID COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| US-4507315-A | Hypoglycaemic and hypolipidaemic benzamide substituted (1H-) imidazole derivatives and compositions | MAY & BAKER LIMITED (GB) | 1985-03-26 | — | — | US | disclosed |
| US-4489089-A | INHIBITION OF THE ENZYME THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0127727-A2 | Substituted N-(omega-(1H-imidazol-1-yl)alkyl)) amides | AMERICAN CYANAMID COMPANY (US) | 1984-12-12 | — | — | EP | disclosed |
| EP-0117462-A2 | N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides | AMERICAN CYANAMID COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283073-A1 | Circular RNA Compositions and Methods | U2AF1, RBM17, RBM22 | KDM4E 2229/4885KMT2A 2714/4885CYP19A1 886/4885 |
| US-12297285-B2 | Circular RNA encoding chimeric antigen receptors targeting BCMA | RBM17, BCR, BCDIN3D | KDM4E 2415/4885KMT2A 1561/4885CYP19A1 416/4885 |
| US-20250268828-A1 | Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides | ABCB4, CETP, HDLBP | KDM4E 4289/4885KMT2A 3198/4885CYP19A1 4350/4885 |
| US-20240052049-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | RBM17, BCR, BCDIN3D | KDM4E 2415/4885KMT2A 1561/4885CYP19A1 416/4885 |
| US-20240042015-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | U2AF1, RBM17, RBM22 | KDM4E 2229/4885KMT2A 2714/4885CYP19A1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.